Kenneth Stallman, MD
Urology · San Antonio, TXNPI 1871575100
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (54.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 86.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $3,715 and has fallen 91.2% since, to $328 in 2025.
Across 33 payments — averaging $166.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- SN Holdings, LLC$142
- Profound Medical Corp.$141
- Biotissue Holdings Inc.$110
- Angiodynamics, Inc.$74
- Novartis$62
- plus $236 from 7 others
Across 174 payments — averaging $7500.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medivation LLC.$1.1M
- Pfizer$157K
- Bayer$14K
What the payments were for
- Travel & lodging$1,58129%
- Food & beverage$90617%
- Education$3,00055%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $4,723 |
| SN Holdings, LLC | 1 | $142 |
| Profound Medical Corp. | 1 | $141 |
| Biotissue Holdings Inc. | 1 | $110 |
| Angiodynamics, Inc. | 1 | $74 |
| Novartis | 2 | $62 |
| Blue Earth Diagnostics | 2 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Dornier Medtech America, Inc | 1 | $42 |
| AstraZeneca | 1 | $29 |
| Dendreon Pharmaceuticals LLC | 1 | $23 |
| Antares Pharma, Inc. | 1 | $19 |
| Mission Pharmacal Company | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$3,000
- Da Vinci Surgical System$1,437
- Tulsa-Pro$141
- NEOX$110
- CLARIX$110
How this compares
$5,488 in reported general payments places this provider in the 60th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 173 | $2,450,582 |
| XtandiEnzalutamide | 37 | $527,743 |
| NubeqaDarolutamide | 24 | $314,700 |
| OrgovyxRelugolix | 116 | $300,337 |
| TrelstarTriptorelin Pamoate | 61 | $143,254 |
| MyrbetriqMirabegron | 91 | $98,020 |
| GemtesaVibegron | 62 | $50,799 |
| Nilutamide | 12 | $27,005 |
| Tamsulosin Hcl | 840 | $13,053 |
| Solifenacin Succinate | 159 | $8,636 |
| Tolterodine Tartrate ErTolterodine Tartrate | 46 | $4,593 |
| Finasteride | 372 | $4,208 |
| Abiraterone Acetate | 16 | $4,193 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 89 | $2,722 |
| Testosterone Cypionate | 21 | $2,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $51 | $351,136178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 878 urology providers in Texas.
Other urology in San Antonio
- Daniel SaltzsteinSan Antonio$547K
- Leroy JonesSan Antonio$506K
- Jose de la CerdaSan Antonio$278K
- Naveen KellaSan Antonio$84K
- Christopher CantrillSan Antonio$73K
- Robert SvatekSan Antonio$51K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.